Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    Chromium Cr-51

    go.drugbank.com/drugs/DB11140
    ApprovedInvestigational

    It is used as a diagnostic radiopharmaceutical agent in nephrology to determine glomerular filtration rate,[A249765,A249770] and in hematology to determine red blood cell volume or mass, study the red … Chromium Cr-51 is an isotope of chromium that has been used as a radioactive label for decades.

  2. Drug

    Triptorelin

    go.drugbank.com/drugs/DB06825
    ApprovedInvestigationalVet approved

    Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. … After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis.

    Products: Triptofem 0,1 mg/ml Injektionslösung in einer Fertigspritze, Decapeptyl Depot - Retardmikrokapseln und Suspensionsmittel in Einmalspritzen
  3. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  4. Drug

    Cinoxacin

    go.drugbank.com/drugs/DB00827
    ApprovedWithdrawn

    Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.

  5. Drug

    Irsogladine

    go.drugbank.com/drugs/DB13056
    Investigational

    Irsogladine is under investigation in clinical trial NCT02581696 (The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers).

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.

  7. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  8. Drug

    Influenza A virus A/Tasmania/503/2020 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB16726
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15507
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  10. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas. … a key role in metastasis and primary tumor growth of breast, gastric, colon cancer, and various other solid tumors.